Methoctramine tetrahydrochloride is a potent and cardioselectivity antagonist of M2 muscarinic receptor . Methoctramine tetrahydrochloride can inhibit Muscarine-induced bradycardia in vivo.

Methoctramine tetrahydrochloride attenuates Acetylcholine (ACh)- and Arecaidine propargyl ester (APE)-induced increases in PG synthesis in a concentration-dependent manner[1]. Methoctramine (0.01-1 μM) tetrahydrochloride causes facilitation of contractions induced by both pre- and postganglionic nerve stimulation in the guinea-pig isolated, innervated tracheal tube preparation[2]. Methoctramine (≥10 μM) tetrahydrochloride reduces responses to both nerve stimulation and exogenous ACh[2].

Methoctramine (300 μg/kg; i.v.) tetrahydrochloride strongly inhibits the Methacholine- and Muscarine-induced bradycardia in the anaesthetized rat, respectively[3].

104807-46-7

C36H63ClN4O2

619.38

Methoctramine tetrahydrochloride

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years